Search results for "Hepatocellular"

showing 10 items of 885 documents

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

2020

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional surviva…

macro-vascular portal vein invasionMaleCarcinoma HepatocellularAntineoplastic Agentsextra hepatic disease and BCLCsurvivalNLRAntineoplastic AgentCohort Studiesalpha-fetoproteinHumansLymphocyte CountSurvivorsprognostic factorAgedLiver NeoplasmsMiddle AgedSorafenibProgression-Free SurvivalItalyLiver Neoplasmalpha-fetoprotein; extra hepatic disease and BCLC; hepatitis C; macro-vascular portal vein invasion; NLR; prognostic factor; survivalFemaleCohort Studiehepatitis CCarcinoma Hepatocellular ...Liver Neoplasms ...Human
researchProduct

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.

2021

BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load. METHODS Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N = 542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pre-treatment serum HBV DNA and HCV RNA were quantified using Roche CO…

medicine.medical_specialtyCarcinoma Hepatocellular610 Medizin610 Medicine & healthChronic liver diseaseAntibodies Monoclonal HumanizedGastroenterologyRamucirumab03 medical and health sciencesLiver disease0302 clinical medicine610 Medical sciencesInternal medicineMedicineHumans030304 developmental biology0303 health sciencesHepatologybusiness.industryLiver NeoplasmsHepatitis CHepatitis Bmedicine.diseasedigestive system diseases3. Good healthClinical Trials Phase III as Topic030220 oncology & carcinogenesisHepatocellular carcinomaLiver functionbusinessViral load
researchProduct

Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study.

2019

BACKGROUND AND AIMS Deciding when to repeat and when to stop transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) can be difficult even for experienced investigators. Our aim was to develop a survival prediction model for such patients undergoing TACE using novel machine learning algorithms and to compare it to conventional prediction scores, ART, ABCR and SNACOR. METHODS For this retrospective analysis, 282 patients who underwent TACE for HCC at our tertiary referral centre between January 2005 and December 2017 were included in the final analysis. We built an artificial neural network (ANN) including all parameters used by the aforementioned risk scores a…

medicine.medical_specialtyCarcinoma Hepatocellular610 MedizinPilot Projects03 medical and health sciences0302 clinical medicine610 Medical sciencesmedicineHumansIn patientInternal validationChemoembolization TherapeuticRetrospective StudiesHepatologyArtificial neural networkbusiness.industryLiver NeoplasmsPatient survivalClinical routinemedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyRadiologyNeural Networks ComputerbusinessArea under the roc curvePredictive modellingLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1)

1995

Abstract Recently, a novel cytokine, cardiotrophin-1 (CT-1), was cloned and found to induce cardiac myocyte hypertrophy in vitro. Amino acid sequence similarity showed CT-1 to be a member of the IL-6/LIF/CNTF/OSM/IL-11 cytokine family. Since all known members of the IL-6 cytokine family induce an hepatic acute phase protein (APP) gene expression, we investigated the ability of CT-1 to induce a liver acute phase response. Upon stimulation of rat hepatoma cells, CT-1 and LIF induced the strongest rat fibrinogen mRNA expression, OSM and IL-6 induced a less pronounced response. When human hepatoma cells and primary rat hepatocytes were stimulated with CT-1, the expression of human haptoglobin a…

medicine.medical_specialtyCarcinoma HepatocellularCardiotrophin 1medicine.medical_treatmentBiophysicsGene ExpressionCiliary neurotrophic factorBiochemistryCardiotrophin 1Structural BiologyInternal medicineGene expressionGeneticsmedicineTumor Cells CulturedAnimalsHumansHepatocyteInterleukin 6Molecular BiologybiologyInterleukin-6Acute-phase proteinCell BiologyMolecular biologyMacroglobulinRatsmedicine.anatomical_structureEndocrinologyCytokineHepatocytebiology.proteinCytokinesInterleukin-6-cytokine familyAcute-Phase ProteinsAcute-phase responseFEBS Letters
researchProduct

Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells

2007

The role of mast cells in tumor growth is still controversial. In this study we analyzed the effects of both histamine and pre-formed mediators spontaneously released by mast cells on the growth of two human hepatocellular carcinoma cell lines, HA22T/VGH and HuH-6, with different characteristics of differentiation, biological behavior and genetic defects. We showed that total mast cell releasate, exocytosed granules (granule remnants) and histamine reduced cell viability and proliferation in HuH-6 cells. In contrast, in HA22T/VGH cells granule remnants and histamine induced a weak but significant increase in cell growth. We showed that both cell lines expressed histamine receptors H(1) and …

medicine.medical_specialtyCarcinoma HepatocellularCell SurvivalSurvivinClinical BiochemistryHistamine AntagonistsApoptosisHistamine H1 receptorBiologyRanitidineBiochemistryExocytosisInhibitor of Apoptosis ProteinsHistamine receptorchemistry.chemical_compoundInternal medicineCell Line TumormedicineAnimalsHumansHistamine H4 receptorMast CellsEnterochromaffin-like cellRats WistarMolecular BiologyCells Culturedbeta CateninCell ProliferationCell growthCaspase 3Liver NeoplasmsMast cellMolecular biologyNeoplasm ProteinsRatsEnzyme ActivationEndocrinologymedicine.anatomical_structurechemistryCell cultureCyclooxygenase 2Molecular MedicineReceptors HistamineFemaleTerfenadinePoly(ADP-ribose) PolymerasesMicrotubule-Associated ProteinsHistamineHistamine
researchProduct

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

2021

ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk fac…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineantiviral therapymedicineHumansPropensity Scoreantiviral therapy; hepatocellular carcinoma; meta-analysisbusiness.industryLiver NeoplasmsGastroenterologyAntiviral therapyPatient datahepatocellular carcinomamedicine.disease3. Good healthmeta-analysis030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinomaRelative riskCohort030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeoplasm Recurrence LocalbusinessDirect acting
researchProduct

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multi…

2017

Purpose To determine in a large multicenter multireader setting the interreader reliability of Liver Imaging Reporting and Data System (LI-RADS) version 2014 categories, the major imaging features seen with computed tomography (CT) and magnetic resonance (MR) imaging, and the potential effect of reader demographics on agreement with a preselected nonconsecutive image set. Materials and Methods Institutional review board approval was obtained, and patient consent was waived for this retrospective study. Ten image sets, comprising 38-40 unique studies (equal number of CT and MR imaging studies, uniformly distributed LI-RADS categories), were randomly allocated to readers. Images were acquired…

medicine.medical_specialtyCarcinoma HepatocellularDatabases FactualIntraclass correlationMedical and Health Sciences030218 nuclear medicine & medical imaging03 medical and health sciencesDatabases0302 clinical medicineClinical ResearchRadiologistsmedicineHumansRadiology Nuclear Medicine and imagingTomographyReliability (statistics)FactualRetrospective StudiesCancerObserver Variationmedicine.diagnostic_testbusiness.industryCarcinomaLiver NeoplasmsReproducibility of ResultsMagnetic resonance imagingRetrospective cohort studyHepatocellularInstitutional review boardMagnetic Resonance ImagingConfidence intervalX-Ray ComputedNuclear Medicine & Medical ImagingPrivate practiceFeature (computer vision)030220 oncology & carcinogenesisBiomedical ImagingCarcinoma Hepatocellular Databases Factual Humans Liver Neoplasms Magnetic Resonance Imaging Observer Variation Radiologists Reproducibility of Results Retrospective Studies Tomography X-Ray Computed AlgorithmsRadiologyTomography X-Ray ComputedbusinessDigestive DiseasesAlgorithms
researchProduct

Screening and surveillance for hepatocellular carcinoma: perspective of a new era?

2016

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death with an increasing prevalence worldwide. Early diagnosis of HCC is important since observational studies have reported that, in patients undergoing surveillance, cancer is diagnosed at an earlier stage with increased chances of curative therapies. Anyway, despite the extensive use of screening for HCC, its effectiveness is still a controversial topic since supporting evidence is not unequivocal and some issues need to be explored. Areas covered: The aim of this paper is to review main literature data supporting performance and effectiveness of screening for early detection …

medicine.medical_specialtyCarcinoma HepatocellularEarly detectionGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMass ScreeningPharmacology (medical)In patientStage (cooking)Intensive care medicineCancer specific mortalityEarly Detection of CancerNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryLiver NeoplasmsCancermedicine.diseasedigestive system diseasesOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation Surveillance030211 gastroenterology & hepatologyObservational studybusinessExpert review of anticancer therapy
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct